Protagonist Therapeutics Inc
PTGX85.400USD
+1.200+1.43%
Close 11/21, 16:00（ET）Quotes delayed by 15 min
5.29BMarket Cap
10.01P/E TTM
More Details of Protagonist Therapeutics Inc Company
Protagonist Therapeutics, Inc. is a biopharmaceutical company. The Company uses its peptide-based chemical entities rusfertide and JNJ-2113 in different stages of development, all derived from its proprietary discovery technology platform. The Company’s clinical programs fall into two categories of diseases: hematology and blood disorders, and inflammatory and immunomodulatory diseases. Its lead clinical asset, rusfertide (PTG-300), is an injectable hepcidin mimetic in development for the potential treatment of polycythemia vera (PV) and other blood disorders. The Company’s Interleukin-23 receptor (IL-23R) antagonist compound JNJ-2113 is an orally delivered investigational drug that is designed to block biological pathways targeted by marketed injectable antibody drugs. Its PN-943 is a wholly owned investigational orally delivered gut-restricted alpha 4 beta 7 (α4β7) specific integrin antagonist for inflammatory bowel disease (IBD).
Protagonist Therapeutics Inc Info
Ticker SymbolPTGX
Company nameProtagonist Therapeutics Inc
IPO dateAug 11, 2016
CEODr. Dinesh V. Patel, Ph.D.
Number of employees126
Security typeOrdinary Share
Fiscal year-endAug 11
Address7707 Gateway Blvd Ste 140
CityNEWARK
Stock exchangeNASDAQ Global Market Consolidated
CountryUnited States of America
Postal code94560-1160
Phone15104740170
Websitehttps://www.protagonist-inc.com/
Ticker SymbolPTGX
IPO dateAug 11, 2016
CEODr. Dinesh V. Patel, Ph.D.
Company Executives of Protagonist Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Dinesh V. Patel, Ph.D.
Dr. Dinesh V. Patel, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
313.60K
-0.20%
Mr. Suneel Gupta, Ph.D.
Mr. Suneel Gupta, Ph.D.
Executive Vice President - Clinical Development
Executive Vice President - Clinical Development
244.41K
+6.14%
Dr. Harold E. (Barry) Selick, Ph.D.
Dr. Harold E. (Barry) Selick, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
38.72K
+38.31%
Mr. Asif Ali
Mr. Asif Ali
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
4.87K
-26.51%
Dr. Arturo Molina, M.D.
Dr. Arturo Molina, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Bryan M. Giraudo
Mr. Bryan M. Giraudo
Independent Director
Independent Director
--
--
Ms. Sarah A. O'Dowd
Ms. Sarah A. O'Dowd
Independent Director
Independent Director
--
-100.00%
Mr. William D. Waddill
Mr. William D. Waddill
Independent Director
Independent Director
--
--
Mr. Corey Davis, Ph.D.
Mr. Corey Davis, Ph.D.
IR Contact Officer
IR Contact Officer
--
--
Dr. Lewis T. Williams ,M.D., Ph.D.
Dr. Lewis T. Williams ,M.D., Ph.D.
Independent Director
Independent Director
--
-100.00%
Name
Name/Position
Position
Shareholding
Change
Dr. Dinesh V. Patel, Ph.D.
Dr. Dinesh V. Patel, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
313.60K
-0.20%
Mr. Suneel Gupta, Ph.D.
Mr. Suneel Gupta, Ph.D.
Executive Vice President - Clinical Development
Executive Vice President - Clinical Development
244.41K
+6.14%
Dr. Harold E. (Barry) Selick, Ph.D.
Dr. Harold E. (Barry) Selick, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
38.72K
+38.31%
Mr. Asif Ali
Mr. Asif Ali
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
4.87K
-26.51%
Dr. Arturo Molina, M.D.
Dr. Arturo Molina, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Bryan M. Giraudo
Mr. Bryan M. Giraudo
Independent Director
Independent Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Wed, Nov 19
Updated: Wed, Nov 19
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
12.83%
Farallon Capital Management, L.L.C.
9.91%
RTW Investments L.P.
9.21%
The Vanguard Group, Inc.
6.79%
State Street Investment Management (US)
5.06%
Other
56.19%
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
12.83%
Farallon Capital Management, L.L.C.
9.91%
RTW Investments L.P.
9.21%
The Vanguard Group, Inc.
6.79%
State Street Investment Management (US)
5.06%
Other
56.19%
Shareholder Types
Shareholders
Proportion
Investment Advisor
38.79%
Investment Advisor/Hedge Fund
35.88%
Hedge Fund
27.18%
Research Firm
5.73%
Venture Capital
4.41%
Private Equity
1.74%
Pension Fund
1.09%
Individual Investor
1.01%
Bank and Trust
0.33%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
551
71.95M
115.09%
-3.63M
2025Q2
533
68.00M
109.30%
-9.94M
2025Q1
541
67.25M
108.51%
-8.96M
2024Q4
503
65.58M
106.87%
-12.21M
2024Q3
480
64.24M
108.98%
-11.36M
2024Q2
419
61.14M
104.21%
-15.61M
2024Q1
412
61.98M
106.36%
-12.46M
2023Q4
402
59.53M
103.21%
-16.02M
2023Q3
400
59.06M
102.70%
-14.36M
2023Q2
411
59.30M
103.68%
-17.88M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
BlackRock Institutional Trust Company, N.A.
8.46M
13.6%
-140.21K
-1.63%
Jun 30, 2025
Farallon Capital Management, L.L.C.
6.17M
9.92%
+65.00K
+1.06%
Jun 30, 2025
RTW Investments L.P.
5.76M
9.25%
+36.86K
+0.64%
Jun 30, 2025
The Vanguard Group, Inc.
4.35M
6.99%
+80.38K
+1.88%
Jun 30, 2025
State Street Investment Management (US)
3.21M
5.16%
+500.92K
+18.51%
Jun 30, 2025
BVF Partners L.P.
3.21M
5.16%
+636.03K
+24.70%
Jun 30, 2025
Johnson & Johnson Innovation-JJDC, Inc.
2.45M
3.94%
--
--
Jun 30, 2025
Wellington Management Company, LLP
1.04M
1.67%
+50.37K
+5.10%
Jun 30, 2025
UBS Financial Services, Inc.
2.50M
4.02%
+2.15M
+619.02%
Jun 30, 2025
Deep Track Capital LP
3.25M
5.22%
-4.10K
-0.13%
Jun 30, 2025
View more
Related ETFs
Updated: Thu, Nov 6
Updated: Thu, Nov 6
Name
Proportion
Invesco S&P SmallCap Health Care ETF
2.47%
ALPS Medical Breakthroughs ETF
2.39%
Invesco S&P SmallCap 600 Pure Growth ETF
2.24%
Invesco Dorsey Wright Healthcare Momentum ETF
2.13%
ETC 6 Meridian Small Cap Equity ETF
1.29%
SPDR S&P Biotech ETF
1.28%
Cambria Value and Momentum ETF
1%
Virtus LifeSci Biotech Clinical Trials ETF
0.85%
Invesco S&P SmallCap Momentum ETF
0.77%
Direxion Daily S&P Biotech Bull 3X Shares
0.67%
View more
Invesco S&P SmallCap Health Care ETF
Proportion2.47%
ALPS Medical Breakthroughs ETF
Proportion2.39%
Invesco S&P SmallCap 600 Pure Growth ETF
Proportion2.24%
Invesco Dorsey Wright Healthcare Momentum ETF
Proportion2.13%
ETC 6 Meridian Small Cap Equity ETF
Proportion1.29%
SPDR S&P Biotech ETF
Proportion1.28%
Cambria Value and Momentum ETF
Proportion1%
Virtus LifeSci Biotech Clinical Trials ETF
Proportion0.85%
Invesco S&P SmallCap Momentum ETF
Proportion0.77%
Direxion Daily S&P Biotech Bull 3X Shares
Proportion0.67%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Protagonist Therapeutics Inc?
The top five shareholders of Protagonist Therapeutics Inc are:
BlackRock Institutional Trust Company, N.A. holds 8.46M shares, accounting for 13.60% of the total shares.
Farallon Capital Management, L.L.C. holds 6.17M shares, accounting for 9.92% of the total shares.
RTW Investments L.P. holds 5.76M shares, accounting for 9.25% of the total shares.
The Vanguard Group, Inc. holds 4.35M shares, accounting for 6.99% of the total shares.
State Street Investment Management (US) holds 3.21M shares, accounting for 5.16% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 8.46M shares, accounting for 13.60% of the total shares.
Farallon Capital Management, L.L.C. holds 6.17M shares, accounting for 9.92% of the total shares.
RTW Investments L.P. holds 5.76M shares, accounting for 9.25% of the total shares.
The Vanguard Group, Inc. holds 4.35M shares, accounting for 6.99% of the total shares.
State Street Investment Management (US) holds 3.21M shares, accounting for 5.16% of the total shares.
What are the top three shareholder types of Protagonist Therapeutics Inc?
The top three shareholder types of Protagonist Therapeutics Inc are:
BlackRock Institutional Trust Company, N.A.
Farallon Capital Management, L.L.C.
RTW Investments L.P.
BlackRock Institutional Trust Company, N.A.
Farallon Capital Management, L.L.C.
RTW Investments L.P.
How many institutions hold shares of Protagonist Therapeutics Inc (PTGX)?
As of 2025Q3, 551 institutions hold shares of Protagonist Therapeutics Inc, with a combined market value of approximately 71.95M, accounting for 115.09% of the total shares. Compared to 2025Q2, institutional shareholding has increased by 5.78%.
What is the biggest source of revenue for Protagonist Therapeutics Inc?
In --, the -- business generated the highest revenue for Protagonist Therapeutics Inc, amounting to -- and accounting for --% of total revenue.
